X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
phenylurea compounds - administration & dosage (1005) 1005
humans (901) 901
index medicus (777) 777
niacinamide - analogs & derivatives (705) 705
niacinamide - administration & dosage (674) 674
male (623) 623
female (568) 568
oncology (454) 454
middle aged (446) 446
sorafenib (434) 434
aged (401) 401
antineoplastic agents - administration & dosage (354) 354
animals (325) 325
adult (297) 297
treatment outcome (294) 294
phenylurea compounds - adverse effects (286) 286
cancer (275) 275
liver neoplasms - drug therapy (266) 266
carcinoma, hepatocellular - drug therapy (246) 246
antineoplastic combined chemotherapy protocols - therapeutic use (218) 218
liver neoplasms - pathology (196) 196
phenylurea compounds - pharmacology (190) 190
niacinamide - adverse effects (189) 189
protein kinase inhibitors - administration & dosage (187) 187
carcinoma, hepatocellular - pathology (183) 183
phenylurea compounds - therapeutic use (183) 183
mice (182) 182
hepatocellular carcinoma (181) 181
antineoplastic agents (161) 161
cell line, tumor (159) 159
pharmacology & pharmacy (159) 159
aged, 80 and over (157) 157
antimitotic agents (157) 157
disease-free survival (154) 154
chemotherapy (148) 148
antineoplastic agents - adverse effects (146) 146
care and treatment (143) 143
antineoplastic agents - therapeutic use (138) 138
therapy (132) 132
dose-response relationship, drug (126) 126
carcinoma, renal cell - drug therapy (120) 120
niacinamide - therapeutic use (120) 120
analysis (118) 118
metastasis (118) 118
hepatoma (114) 114
survival (114) 114
pyridines - administration & dosage (113) 113
kidney neoplasms - drug therapy (110) 110
liver cancer (110) 110
angiogenesis (107) 107
medicine & public health (102) 102
retrospective studies (102) 102
antineoplastic combined chemotherapy protocols - adverse effects (101) 101
neoplasm staging (101) 101
phenylurea compounds - pharmacokinetics (101) 101
tumors (101) 101
apoptosis (99) 99
sunitinib (97) 97
prognosis (96) 96
cell proliferation - drug effects (93) 93
apoptosis - drug effects (92) 92
combination (89) 89
digestive system diseases (89) 89
niacinamide - pharmacology (89) 89
protein kinase inhibitors - adverse effects (89) 89
trial (88) 88
xenograft model antitumor assays (87) 87
bevacizumab (86) 86
indoles - administration & dosage (86) 86
antineoplastic combined chemotherapy protocols - administration & dosage (85) 85
article (84) 84
drug synergism (84) 84
neoplasms (84) 84
drug therapy (83) 83
efficacy (82) 82
kaplan-meier estimate (82) 82
kidney neoplasms - pathology (80) 80
cancer therapies (79) 79
expression (79) 79
vascular endothelial growth factor (79) 79
administration, oral (78) 78
pyrroles - administration & dosage (77) 77
drug administration schedule (76) 76
neoplasm metastasis (75) 75
rats (74) 74
research (73) 73
clinical trials (72) 72
colorectal neoplasms - drug therapy (71) 71
cancer research (70) 70
disease progression (70) 70
young adult (68) 68
protein kinase inhibitors - therapeutic use (66) 66
hematology, oncology and palliative medicine (65) 65
patients (65) 65
antineoplastic agents - pharmacology (64) 64
liver neoplasms - mortality (64) 64
carcinoma, hepatocellular - therapy (63) 63
liver neoplasms - therapy (63) 63
mutation (63) 63
safety (63) 63
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (989) 989
Japanese (29) 29
Chinese (12) 12
German (7) 7
French (5) 5
Russian (4) 4
Italian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 319 - 328
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 2, pp. 157 - 157
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 6, pp. 619 - 629
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2016, Volume 64, Issue 5, pp. 1090 - 1098
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | LIVER-TRANSPLANTATION | RISK-FACTORS | THERAPY | MANAGEMENT | ONCOLOGY | SAFETY | PREVENTION | RECURRENCE | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 7, pp. 1646 - 1658.e17
Journal Article